Mindpeak, Proscia Revolutionize Cancer Research Using AI
HAMBURG – According to a press release, German AI software provider Mindpeak has partnered with Proscia, an American digital pathology solutions company, to enhance the field of cancer diagnosis using AI. Their collaboration will streamline the workflow of pathologists by integrating AI technology into the analysis of digital pathology images, ultimately leading to more efficient clinical decisions.
According to the latest data from GlobalData’s Clinical Trials Database, there are currently 1,490 active clinical trials for in vitro diagnostics (IVD) devices, out of which 569 trials are dedicated to oncology diagnostic devices. Among these, nine trials involve analysis or partial analysis.
Recognizing the importance of advancing cancer diagnostics, the partnership will utilize Mindpeak’s cutting-edge breast cancer detection software, known as BreatHC, in conjunction with Proscia’s open digital pathology platform, Concentriq Dx. The collaborative effort seeks to optimize pathologists’ workflows, empowering them to make more informed clinical decisions based on AI-aided interpretation of patient samples.
With these groundbreaking initiatives paving the way for future advances, GlobalData predicts a trend toward increased adoption of AI technology by IVD manufacturers in the coming decade. Ultimately, integrating AI into medical devices will result in earlier cancer detection and facilitate the administration of highly effective treatments identified by AI algorithms.
